New Market Report Now Available: Canada Pharmaceuticals & Healthcare Report Q1 2011

New Healthcare research report from Business Monitor International is now available from Fast Market Research
Spread the Word
Listed Under

* Pharmaceutical
* Drug
* Healthcare
* Ratings
* Medical
* Generic
* Medicines
* Patented
* Prescription
* Canadian

* Health
* Medical
* Research

* Massachusetts - US

Jan. 14, 2011 - PRLog -- The Canadian economy is still slowing, and BMI's Country Risk team is maintaining its belowconsensus projection for 2011. With fiscal stimulus amounting to 2.9% of GDP over the past two fiscal years, we believe government consumption growth will drop from about 4.1% y-o-y in real terms in H110 to 1.5-2.0% by H111. For 2011 as a whole, we expect government consumption growth to come in at 2.0%. Additionally, we are forecasting 2.3% growth in private consumption in 2011, a sharp slowdown from 3.3% in 2010, but still representing a contribution of 1.5 percentage points (pp) to GDP.

In BMI's Pharmaceutical Business Environment Ratings (BERs) for Q111, Canada remains in second place in the expanded regional matrix, trailing the US by almost four points. On a global scale, Canada also ranks second, after the US and above Switzerland, of the 83 markets surveyed globally. Despite a tightening cost-containment environment and the provincial variations regarding prescription drug subsidies, Canada will remain one of the most attractive pharmaceutical markets on a worldwide scale, in part due to its high per-capita spending on medicines, which topped US$651 in 2009, as well as population expansion and ageing.

Canada's healthcare system is facing serious challenges in terms of affordability and accessibility, as well as failing to meet the medical needs of the country's changing demographics, according to a report released by the Canadian Medical Association (CMA) in August 2010. Extensive reforms are being proposed ahead of the renegotiation of the current Health Accord, which is set to expire on March 31 2014. First Ministers have described the current level of spending on prescription drugs in the National Pharmaceutical Strategy as 'catastrophic', which is expected to lead to some policy changes and further cost-containment initiatives. This is in line with a trend that is beginning to prevail across the developed world, the government remains set on eliminating the deficit by 2014.

Over the next five years, BMI predicts that the Canadian pharmaceutical market will post a compound annual growth rate (CAGR) of 2.26% in local currency terms, reaching CAD28.01bn (US$24.36bn) in value by 2014. Growth over the 2009-2019 period will accelerate to 3.15%, due to a boost to the patented medicines segment in the latter parts of the forecast, driven by the use of more personalised therapies and higher-value medicines.

The generic drug segment, however, will post more modest five- and ten-year CAGRs of 2.75% and 2.51% in local currency terms, respectively, to reach CAD10.61bn (US$9.23bn) by 2019. The weaker growth of generic drugs compared with patented drugs is mainly due to the relatively high prices of generics and their poor consumer perception. Market growth opportunities for the out-of-pocket segment will also remain limited, given the outlook for slow growth in private consumption levels over the medium term.

For more information or to purchase this report, go to:

Partial Table of Contents:

Executive Summary
SWOT Analysis
- Canada Pharmaceuticals And Healthcare Industry SWOT
- Canada Political SWOT
- Canada Economic SWOT
Pharmaceutical Business Environment Ratings
- Table: Americas - Pharmaceuticals Business Environment Ratings, Q111
- Rewards
- Risks
Canada - Market Summary
- Pharmacovigilance
- Biosimilars
- OTC Medicines
- Intellectual Property Regime
- International Collaboration
- Pricing Regime
- Provincial Pricing Systems
- Reimbursement Regime
- Recent Pricing and Reimbursement Developments
Industry Developments
- Epidemiology
- Healthcare Sector
- International Comparison
- Health Expenditure
- Table: Sustainability Of Public Health Expenditure And Pharmaceutical Approval Indicators
- National Pharmaceuticals Strategy
- Pharmaceutical Retail
- Research and Development Sector
- Biotechnology
- Medical Devices Industry
- Recent Developments in the Medical Devices Industry
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2006-2014
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Trends, Historical Data and Forecasts, 2006-2014
- Key Growth Factors - Macroeconomic
- Table: Canada - Economic Activity
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2006-2014
- Patented Product Market Forecast
- Table: Patented Drug Sales Indicators 2006-2014
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2006-2014
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2006-2014
- Medical Device Market Forecast
- Table: Medical Device Sales Indicators 2006-2014
- Pharmaceutical Trade Forecasts
- Table: Pharmaceutical Imports & Exports Indicators 2006-2014
- Other Healthcare Data
Competitive Landscape
- Pharmaceutical Industry
- Pharmaceutical Re-import Policy
- Recent Pharmaceutical Company Developments
- Top 20 Pharmaceutical Companies According To Market Capitalisation On The Canadian Stock Exchange
Company Profiles
- Domestic Manufacturers
- Apotex
- Biovail (Valeant)
- Leading Multinational Manufacturers
- Pfizer
- GlaxoSmithKline

Full Table of Contents is available at:

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:*** Email Verified
Tags:Pharmaceutical, Drug, Healthcare, Ratings, Medical, Generic, Medicines, Patented, Prescription, Canadian
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Fast Market Research News
Daily News
Weekly News

Like PRLog?
Click to Share